Christopher Paul German
Known title: Corporate Controller & CAOCIK: 0001260835
Associated companies
Transaction History
| RYTM | ▲ Buy | Option Exercise | 1,349 | $66K | 5/15/2026 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 1,406 | $25K | 5/15/2026 | View on chart |
| RYTM | ▼ Sell | Open Market | 4,643 | $428K | 5/15/2026 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 1,687 | $96K | 5/15/2026 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 1,500 | $27K | 3/4/2026 | View on chart |
| RYTM | ▼ Sell | Open Market | 5,614 | $503K | 3/4/2026 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 1,162 | — | 3/1/2026 | View on chart |
| RYTM | ▼ Sell | Tax Withholding | 342 | $32K | 3/1/2026 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 3,613 | — | 2/1/2026 | View on chart |
| RYTM | ▼ Sell | Tax Withholding | 1,138 | $124K | 2/1/2026 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 1,000 | $18K | 8/12/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 500 | $25K | 8/12/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 1,500 | $143K | 8/12/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 2,000 | $36K | 7/9/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 850 | $42K | 7/9/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 1,850 | $157K | 7/9/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 1,967 | $151K | 7/9/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 1,069 | $19K | 6/10/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 2,069 | $139K | 6/10/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 344 | $19K | 3/21/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 1,163 | — | 3/20/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 635 | $36K | 2/19/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 1,807 | — | 2/16/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 368 | $15K | 4/2/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 1,163 | — | 3/20/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
RYTM: RBC raises price target to $159, maintains Outperform
RBC Capital kept its Outperform rating on Rhythm Pharmaceuticals and lifted its price target to $159. The new target sits well above the stock’s 52‑week high of $122.20 and higher than the consensus analyst target of $138.59. A recent Benzinga piece also highlighted the stock’s five‑year total return, underscoring its past performance. These developments may influence market perception of the company’s growth prospects.
RYTM: RBC raises price target to $159, maintains Outperform. RBC Capital kept its Outperform rating on Rhythm Pharmaceuticals and lifted its price target to $159. The new target sits well above the stock’s 52‑week high of $122.20 and higher than the consensus analyst target of $138.59. A recent Benzinga piece also highlighted the stock’s five‑year total return, underscoring its past performance. These developments may influence market perception of the company’s growth prospects.